CAR-T therapies show promising clinical responses, yet many patients relapse due to the immunosuppressive tumor microenvironment (TME). Multiple Myeloma remains largely incurable.

OUR SOLUTION
Osteogenic growth peptide (OGP), a selective CB2 agonist, enhances anti-tumor immunity by reducing immunosuppressive myeloid cells and boosting cytotoxic T-cell activity. In preclinical studies, OGP demonstrated synergistic activity with CAR-T therapy, leading to improved tumor control and survival. In collaboration with Dr. Anat Globerson-Levin from Tel Aviv- Sourasky University Medical Center Ichilov.

Key Advantages

• Increases survival
• Reduces tumor number and size
• Decreases tumor-promoting myeloid cells and alleviates the immunosuppressive tumor microenvironment (TME)
• Enhances anti-tumor CD8+ T cells
• Supported by human CNR2 genetic data

Potential Applications

• Multiple Myeloma
• Additional cancers with immunosuppressive TMEs
• Combination therapies with CAR-T and other immunotherapies

Stage of Development

• Preclinical proof-of-concept in vivo and in vitro
• Supporting human genetic evidence

IP Status
International Application No.PCT/IL2025/050869

Publications
https://www.nature.com/articles/s41388-025-03399-9 (Nature Oncogene, 2025)